PE20130527A1 - Polipeptidos de union a a-beta biparatopicos - Google Patents
Polipeptidos de union a a-beta biparatopicosInfo
- Publication number
- PE20130527A1 PE20130527A1 PE2012001380A PE2012001380A PE20130527A1 PE 20130527 A1 PE20130527 A1 PE 20130527A1 PE 2012001380 A PE2012001380 A PE 2012001380A PE 2012001380 A PE2012001380 A PE 2012001380A PE 20130527 A1 PE20130527 A1 PE 20130527A1
- Authority
- PE
- Peru
- Prior art keywords
- cdr
- seq
- biparatopic
- binding polypeptides
- beta binding
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
Abstract
SE REFIERE A UN POLIPEPTIDO QUE COMPRENDE DOS DOMINIOS VARIABLES INDIVIDUALES DE INMUNOGLOBULINAS QUE SE UNEN A -BETA TENIENDO DICHOS DOMINIOS VARIABLES INDIVIDUALES LA ESTRUCTURA: FR(1)1-CDR(1)1-FR(1)2-CDR(1)2-FR(1)3-CDR(1)3-FR(1)4, Y FR(2)1-CDR(2)1-FR(2)2-CDR(2)2-FR(2)3-CDR(2)3-FR(2)4, RESPECTIVAMENTE Y DONDE CDR(1)1: SEC ID Nº 11, 14, 17; CDR(1)2: SEC ID Nº 12, 15, 18; CDR(1)3: SEC ID Nº 13, 16, 19; CDR(2)1: SEC ID Nº 17, 11, 14; CDR(2)2: SEC ID Nº 18, 12, 15; CDR(2)3 SEC ID Nº 19, 13,16 Y FR SON REGIONES FLAQUEANTES. DICHO PRIMER Y SEGUNDO DOMINIO VARIABLE INDIVIDUAL DE INMUNOGLOBULINA ESTAN DEFINIDOS POR LA SEC ID Nº 3 O POR LA SEC ID Nº 4, NO SIENDO LOS EPITOPOS A-BETA IGUALES. REFERIDA ADEMAS A UNA COMPOSICION FARMACEUTICA. DICHO POLIPEPTIDO ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES O TRANSTORNOS NEURODEGENERATIVOS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10155339 | 2010-03-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20130527A1 true PE20130527A1 (es) | 2013-05-09 |
Family
ID=42227600
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2012001380A PE20130527A1 (es) | 2010-03-03 | 2011-03-02 | Polipeptidos de union a a-beta biparatopicos |
Country Status (24)
Country | Link |
---|---|
US (3) | US8337845B2 (es) |
EP (1) | EP2542579A1 (es) |
JP (2) | JP5826194B2 (es) |
KR (1) | KR20130010114A (es) |
CN (1) | CN102781962B (es) |
AP (1) | AP2012006359A0 (es) |
AR (1) | AR080446A1 (es) |
AU (1) | AU2011222980B2 (es) |
BR (1) | BR112012022102A2 (es) |
CA (1) | CA2788275A1 (es) |
CL (1) | CL2012002095A1 (es) |
CO (1) | CO6592094A2 (es) |
EA (1) | EA201201227A1 (es) |
EC (1) | ECSP12012184A (es) |
HK (1) | HK1175184A1 (es) |
MA (1) | MA34025B1 (es) |
MX (1) | MX2012009460A (es) |
NZ (1) | NZ601117A (es) |
PE (1) | PE20130527A1 (es) |
SG (1) | SG183369A1 (es) |
TN (1) | TN2012000434A1 (es) |
TW (1) | TW201144437A (es) |
UY (1) | UY33253A (es) |
WO (1) | WO2011107507A1 (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201144437A (en) | 2010-03-03 | 2011-12-16 | Boehringer Ingelheim Int | A-beta binding polypeptides |
US11644471B2 (en) * | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
WO2012175741A2 (en) * | 2011-06-23 | 2012-12-27 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
WO2012042026A1 (en) | 2010-09-30 | 2012-04-05 | Ablynx Nv | Biological materials related to c-met |
HUE047238T2 (hu) | 2011-06-23 | 2020-04-28 | Ablynx Nv | Szérumalbuminhoz kötõdõ fehérjék |
US9346884B2 (en) | 2011-09-30 | 2016-05-24 | Ablynx N.V. | Biological materials related to c-Met |
JP6247226B2 (ja) | 2012-01-10 | 2017-12-13 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | 血液脳関門を越える治療分子の輸送の向上 |
EP3019192A4 (en) | 2013-07-08 | 2017-07-05 | Nanjingjinsirui Science&Technology Biology Corporation | Compositions and methods for increasing protein half-life in a serum |
KR20230145503A (ko) | 2014-05-16 | 2023-10-17 | 아블린쓰 엔.브이. | 개선된 면역글로불린 가변 도메인 |
SI3143042T1 (sl) | 2014-05-16 | 2020-08-31 | Ablynx N.V. | Variabilne domene imunoglobulina |
CA2966397A1 (en) * | 2014-11-03 | 2016-05-12 | Merck Patent Gmbh | Methods for generating bispecific shark variable antibody domains and use thereof |
WO2016077595A1 (en) * | 2014-11-12 | 2016-05-19 | The General Hospital Corporation | Methods for treating neurodegenerative diseases |
CN104558172A (zh) * | 2015-01-04 | 2015-04-29 | 东南大学 | 一种针对β淀粉样蛋白的单域重链纳米抗体及其应用 |
AU2016215087A1 (en) | 2015-02-06 | 2017-08-17 | University Of Maryland, Baltimore | Tetra-specific, octameric binding agents and antibodies against Clostridium difficile toxin A and toxin B for treatment of C. difficile infection |
US10330650B2 (en) * | 2015-04-28 | 2019-06-25 | Hybio Pharmaceutical Co., Ltd. | High performance liquid chromatography method for polypeptide mixtures |
LT3383425T (lt) | 2015-12-04 | 2020-10-12 | Boehringer Ingelheim International Gmbh | Biparatopiniai polipeptidai, veikiantys antagonistiškai wnt signaliniam keliui vėžinėse ląstelėse |
AU2018276409A1 (en) | 2017-05-31 | 2019-10-31 | Boehringer Ingelheim International Gmbh | Polypeptides antagonizing Wnt signaling in tumor cells |
CA3070253A1 (en) * | 2017-07-19 | 2019-01-24 | Vib Vzw | Serum albumin binding agents |
EP3758755A1 (en) * | 2018-02-26 | 2021-01-06 | Ablynx N.V. | Improved nucleotide sequences encoding peptide linkers |
US20210190796A1 (en) * | 2018-08-17 | 2021-06-24 | Ab Studio Inc. | Catabodies and methods of use thereof |
CA3117409A1 (en) * | 2018-10-29 | 2020-05-07 | Biogen Ma Inc. | Humanized and stabilized fc5 variants for enhancement of blood brain barrier transport |
CN111334480B (zh) * | 2020-05-18 | 2020-09-01 | 苏州仁端生物医药科技有限公司 | 一种分泌抗Aβ1-42单克隆抗体的杂交瘤细胞株及其应用 |
EP4185612A1 (en) | 2020-07-23 | 2023-05-31 | Othair Prothena Limited | Anti-abeta antibodies |
CN113686235B (zh) * | 2021-08-16 | 2022-09-16 | 中国科学院力学研究所 | 一种基于纳米孔过孔电流估计蛋白质构象形貌特征的方法 |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2162823T5 (es) | 1992-08-21 | 2010-08-09 | Vrije Universiteit Brussel | Inmunoglobulinas desprovistas de cadenas ligeras. |
EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
US6329516B1 (en) | 1997-04-28 | 2001-12-11 | Fmc Corporation | Lepidopteran GABA-gated chloride channels |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
WO2001079442A2 (en) | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP1328626B1 (en) | 2000-05-26 | 2013-04-17 | National Research Council Of Canada | Single-domain brain-targeting antibody fragments derived from llama antibodies |
TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
JP4303105B2 (ja) | 2001-06-28 | 2009-07-29 | ドマンティス リミテッド | 二重特異性リガンドとその利用 |
JP4123856B2 (ja) | 2001-07-31 | 2008-07-23 | 日油株式会社 | 生体関連物質の修飾剤およびポリオキシアルキレン誘導体の製造方法 |
WO2003059934A2 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
AR038568A1 (es) * | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
FR2846667B1 (fr) | 2002-11-06 | 2004-12-31 | Pasteur Institut | Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives |
US20060228355A1 (en) | 2003-11-07 | 2006-10-12 | Toon Laeremans | Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor |
EP2316852B1 (en) | 2002-11-08 | 2014-03-05 | Ablynx N.V. | Stabilized single domain antibodies |
EP1558646A2 (en) | 2002-11-08 | 2005-08-03 | Ablynx N.V. | Single domain antibodies directed against interferon- gamma and uses thereof |
DE60329627D1 (de) | 2002-12-31 | 2009-11-19 | Nektar Therapeutics Al Corp | Hydrolysestabile maleimidendgruppen-enthaltende polymere |
KR20050092029A (ko) * | 2003-01-10 | 2005-09-16 | 아블린쓰 엔.브이. | 폰 빌레브란트 인자(vWF) 또는 콜라겐에 대한낙타과로부터의 재조합 VHH 단일 도메인 항체 |
TWI306458B (en) | 2003-05-30 | 2009-02-21 | Elan Pharma Int Ltd | Humanized antibodies that recognize beta amyloid peptide |
AU2004220325B2 (en) | 2003-06-30 | 2011-05-12 | Domantis Limited | Polypeptides |
TWI379839B (en) | 2003-12-17 | 2012-12-21 | Wyeth Llc | Aβ immunogenic peptide carrier conjugates and methods of producing same |
CN101076543A (zh) * | 2004-10-13 | 2007-11-21 | 阿布林克斯公司 | 用于治疗和诊断变性神经疾病如阿尔茨海默症的单结构域骆驼抗淀粉样蛋白β的抗体以及包含它的多肽 |
AU2005293752A1 (en) * | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as Alzheimer's disease |
PE20061152A1 (es) | 2004-12-15 | 2006-10-13 | Neuralab Ltd | Anticuerpos humanizados que reconocen el peptido beta amiloideo |
US20060257396A1 (en) | 2004-12-15 | 2006-11-16 | Jacobsen Jack S | Abeta antibodies for use in improving cognition |
US8916165B2 (en) | 2004-12-15 | 2014-12-23 | Janssen Alzheimer Immunotherapy | Humanized Aβ antibodies for use in improving cognition |
CA2589860A1 (en) | 2005-01-24 | 2006-08-03 | Amgen Inc. | Humanized anti-amyloid antibody |
GT200600031A (es) | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
PE20061323A1 (es) | 2005-04-29 | 2007-02-09 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos |
PL1888640T3 (pl) | 2005-05-18 | 2012-08-31 | Ablynx Nv | Ulepszone nanociała skierowane przeciwko czynnikowi martwicy nowotworów typu alfa |
PT2444424T (pt) * | 2005-05-20 | 2018-11-09 | Ablynx Nv | Nanocorpos tm aperfeiçoados para o tratamento de distúrbios mediados por agregação |
MY169746A (en) * | 2005-08-19 | 2019-05-14 | Abbvie Inc | Dual variable domain immunoglobulin and uses thereof |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
EP1934611A2 (en) | 2005-09-23 | 2008-06-25 | Academisch Ziekenhuis Leiden | Vhh for the diagnosis, prevention and treatment of diseases associated with protein aggregates |
BRPI0619748B8 (pt) | 2005-12-12 | 2021-05-25 | Ac Immune Sa | anticorpo monoclonal, polinucleotídeo, composição, mistura, uso de um anticorpo monoclonal ou uma parte funcional do mesmo, método para preparar uma composição farmacêutica, linhagem celular de hibridoma isolado, método de diagnóstico de uma doença ou condição associada a amilóide em um paciente, método para diagnosticar uma predisposição para uma doença ou condição, método para monitorar doença residual mínima, método para prever a responsividade de um paciente e kits de teste |
NZ568241A (en) | 2005-12-12 | 2011-08-26 | Hoffmann La Roche | Antibodies against amyloid beta 4 with glycosylation in the variable region |
PT1996621E (pt) | 2006-03-30 | 2010-03-08 | Glaxo Group Ltd | Anticorpos contra o péptido beta-amilóide |
CA2657681C (en) | 2006-07-14 | 2019-03-19 | Ac Immune S.A. | Humanized antibodies against beta amyloid protein |
WO2008020079A1 (en) | 2006-08-18 | 2008-02-21 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
JP2010511397A (ja) | 2006-12-05 | 2010-04-15 | アブリンクス エン.ヴェー. | 血清タンパク質と結合可能なペプチド |
JP2010512356A (ja) | 2006-12-11 | 2010-04-22 | エフ.ホフマン−ラ ロシュ アーゲー | 非経口aベータ抗体製剤 |
US8907065B2 (en) * | 2006-12-15 | 2014-12-09 | Ablynx N.V. | Polypeptides that modulate the interaction between cells of the immune system |
SI2842967T1 (sl) | 2007-01-18 | 2017-01-31 | Eli Lilly And Company | Pegilirani amiloid beta fab |
EP1978035A1 (en) | 2007-04-05 | 2008-10-08 | Hans-Knöll-Institut Leibniz-Institut für Naturstoff-Forschung | Anti-amyloid antibodies and their use in diagnosis and therapy of amyloid diseases |
KR101264473B1 (ko) * | 2007-05-24 | 2013-05-29 | 아블린쓰 엔.브이. | Rank-l에 대한 아미노산 서열, 및 이를 포함하는 골 질환 및 장애 치료용 폴리펩티드 |
US20090175847A1 (en) | 2007-05-30 | 2009-07-09 | Abbott Laboratories | Humanized antibodies to ab (20-42) globulomer and uses thereof |
TWI453217B (zh) | 2007-06-12 | 2014-09-21 | Ac Immune Sa | 抗β類澱粉蛋白單株抗體 |
WO2008156622A1 (en) | 2007-06-12 | 2008-12-24 | Ac Immune S.A. | Humanized antibodies to amyloid beta |
EP2009445A1 (en) | 2007-06-29 | 2008-12-31 | Institut Pasteur | Use of a camelid single-domain antibody for detecting an oligomeric form of an amyloid beta peptide and its applications |
EP2008666A1 (en) * | 2007-06-29 | 2008-12-31 | Institut Pasteur | Use of VHH antibodies for the preparation of peptide vectors for delivering a substance of interest and their applications |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
AU2008317705B2 (en) | 2007-10-29 | 2014-06-05 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | New antibodies specific of the beta-amyloid peptides and their uses as diagnostic agents or drugs |
EP2215125A1 (en) * | 2007-11-27 | 2010-08-11 | Ablynx N.V. | Method for obtaining polypeptide constructs comprising two or more single domain antibodies |
CN101965362A (zh) | 2008-03-05 | 2011-02-02 | 埃博灵克斯股份有限公司 | 新型抗原结合二聚体-复合物及其制备方法和应用 |
EP2268668A1 (en) | 2008-04-17 | 2011-01-05 | Ablynx N.V. | Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same |
BRPI0913366A8 (pt) * | 2008-06-03 | 2017-07-11 | Abbott Lab | Imunoglobulinas de domínio variável duplo e seus usos |
TW201144437A (en) | 2010-03-03 | 2011-12-16 | Boehringer Ingelheim Int | A-beta binding polypeptides |
-
2011
- 2011-03-02 TW TW100106954A patent/TW201144437A/zh unknown
- 2011-03-02 AU AU2011222980A patent/AU2011222980B2/en not_active Ceased
- 2011-03-02 EA EA201201227A patent/EA201201227A1/ru unknown
- 2011-03-02 US US13/038,471 patent/US8337845B2/en active Active
- 2011-03-02 UY UY0001033253A patent/UY33253A/es not_active Application Discontinuation
- 2011-03-02 AR ARP110100659A patent/AR080446A1/es unknown
- 2011-03-02 BR BR112012022102A patent/BR112012022102A2/pt not_active IP Right Cessation
- 2011-03-02 KR KR1020127023071A patent/KR20130010114A/ko not_active Application Discontinuation
- 2011-03-02 NZ NZ601117A patent/NZ601117A/en not_active IP Right Cessation
- 2011-03-02 MX MX2012009460A patent/MX2012009460A/es not_active Application Discontinuation
- 2011-03-02 PE PE2012001380A patent/PE20130527A1/es not_active Application Discontinuation
- 2011-03-02 MA MA35176A patent/MA34025B1/fr unknown
- 2011-03-02 CA CA2788275A patent/CA2788275A1/en not_active Abandoned
- 2011-03-02 EP EP11708226A patent/EP2542579A1/en not_active Ceased
- 2011-03-02 CN CN201180012034.7A patent/CN102781962B/zh not_active Expired - Fee Related
- 2011-03-02 WO PCT/EP2011/053090 patent/WO2011107507A1/en active Application Filing
- 2011-03-02 SG SG2012061024A patent/SG183369A1/en unknown
- 2011-03-02 AP AP2012006359A patent/AP2012006359A0/xx unknown
- 2011-03-02 JP JP2012555410A patent/JP5826194B2/ja not_active Expired - Fee Related
-
2012
- 2012-07-27 CL CL2012002095A patent/CL2012002095A1/es unknown
- 2012-08-31 TN TNP2012000434A patent/TN2012000434A1/en unknown
- 2012-09-04 CO CO12151313A patent/CO6592094A2/es unknown
- 2012-09-14 US US13/617,248 patent/US8614308B2/en active Active
- 2012-09-27 EC ECSP12012184 patent/ECSP12012184A/es unknown
-
2013
- 2013-02-26 HK HK13102375.6A patent/HK1175184A1/xx not_active IP Right Cessation
- 2013-08-29 US US14/013,364 patent/US9211330B2/en active Active
-
2015
- 2015-07-06 JP JP2015134933A patent/JP2015180691A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US9211330B2 (en) | 2015-12-15 |
KR20130010114A (ko) | 2013-01-25 |
AR080446A1 (es) | 2012-04-11 |
BR112012022102A2 (pt) | 2017-01-10 |
TN2012000434A1 (en) | 2014-01-30 |
US8337845B2 (en) | 2012-12-25 |
EA201201227A1 (ru) | 2013-04-30 |
CA2788275A1 (en) | 2011-09-09 |
EP2542579A1 (en) | 2013-01-09 |
US20120058118A1 (en) | 2012-03-08 |
HK1175184A1 (en) | 2013-06-28 |
TW201144437A (en) | 2011-12-16 |
MX2012009460A (es) | 2012-09-12 |
US8614308B2 (en) | 2013-12-24 |
AU2011222980A1 (en) | 2012-08-02 |
US20130017209A1 (en) | 2013-01-17 |
MA34025B1 (fr) | 2013-02-01 |
JP2015180691A (ja) | 2015-10-15 |
CO6592094A2 (es) | 2013-01-02 |
AP2012006359A0 (en) | 2012-08-31 |
AU2011222980B2 (en) | 2016-08-11 |
US20140030275A1 (en) | 2014-01-30 |
NZ601117A (en) | 2014-06-27 |
JP2013520974A (ja) | 2013-06-10 |
ECSP12012184A (es) | 2012-10-30 |
WO2011107507A1 (en) | 2011-09-09 |
CN102781962A (zh) | 2012-11-14 |
CL2012002095A1 (es) | 2012-10-19 |
CN102781962B (zh) | 2014-12-10 |
SG183369A1 (en) | 2012-09-27 |
JP5826194B2 (ja) | 2015-12-02 |
UY33253A (es) | 2011-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20130527A1 (es) | Polipeptidos de union a a-beta biparatopicos | |
HRP20200745T1 (hr) | Agensi koji vezuju cd123 i njihove upotrebe | |
PE20190920A1 (es) | Anticuerpos modificados de union a fcrn humano y metodos de utilizacion | |
PE20181363A1 (es) | Variantes optimizadas de anticuerpos anti-vegf | |
EA201991099A1 (ru) | Антитела против cd73 и их применение | |
AR106949A1 (es) | Polipéptidos biparatópicos que antagonizan la señalización wnt en células tumorales | |
PE20200011A1 (es) | ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
RU2016106577A (ru) | САЙТЫ АНТИТЕЛ, СПЕЦИФИЧНО СВЯЗЫВАЮЩИЕ EGFRvIII | |
RU2018136567A (ru) | Активируемые протеазой связывающие т-клетки биспецифические молекулы | |
PE20120899A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b | |
PE20200695A1 (es) | Anticuerpos que reconocen tau | |
ES2572356T3 (es) | Composiciones de anticuerpos dirigidos contra VEGF y procedimientos | |
MX2016015389A (es) | Anticuerpos que se enlazan a cd3 epsilon humano y de mono cinomolgo. | |
RS53042B (en) | ANTIBODIES AGAINST ERBB3 AND THEIR USES | |
PE20110225A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5 | |
EA201891732A1 (ru) | Биспецифичные связывающие белки для pd-l1 и kdr | |
EA201100546A1 (ru) | Полипептиды, вариабельные домены антител и антагонисты | |
EA201290525A1 (ru) | Новые антитела-антагонисты, их fab-фрагменты против gpvi и способы их применения | |
PE20131209A1 (es) | Anticuerpos anti-fap | |
EA201791270A1 (ru) | Модифицированные april-связывающие антитела | |
EA201491571A1 (ru) | МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С АСИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ | |
RU2014122990A (ru) | Способы комбинированной терапии с применением молекул, связывающихся с psl и pcrv pseudomonas | |
AR085091A1 (es) | Anticuerpos anti-kit y sus usos | |
RU2017104642A (ru) | Новое антитело против tie-2 человека | |
JP2015504421A5 (es) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |